Literature DB >> 7645204

Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation.

B Wang1, J Boyer, V Srikantan, K Ugen, L Gilbert, C Phan, K Dang, M Merva, M G Agadjanyan, M Newman.   

Abstract

DNA inoculation has the potential to produce antigens in a native as well as a host-"customized" form for presentation to the immune system. As such this technology may have relevance for vaccine/immune therapeutic strategies for a variety of infectious pathogens. In rodents in vivo inoculation of plasmid expression vectors encoding HIV-1 gene products leads to production of HIV-1 antigens in vivo, resulting in the production of both cellular and humoral immune responses. In primates only preliminary studies of serology have been reported. Here we report further evaluation of this new technology as a method to induce humoral and particularly cellular immune responses against a human pathogen, the HIV-1 virus, in nonhuman primates. Following inoculation and boosting of animals with an HIV gp160 plasmid expression vector we observed the induction of neutralizing responses against two diverse HIV-1 isolates in 2 of 3 vaccinated animals. T cell proliferative responses to HIV antigens were also observed in all plasmid-inoculated animals and specific cross-reactive cytotoxic T lymphocyte responses were developed in vaccinated animals. This report establishes the ability of DNA inoculation to induce cellular immune responses in nonhuman primates and suggests that further investigation of this technology with regard to human vaccine or immune therapeutic development is therefore warranted.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7645204     DOI: 10.1006/viro.1995.1383

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

Authors:  N L Letvin; D C Montefiori; Y Yasutomi; H C Perry; M E Davies; C Lekutis; M Alroy; D C Freed; C I Lord; L K Handt; M A Liu; J W Shiver
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 3.  DNA vaccines: developing new strategies to enhance immune responses.

Authors:  Shaheed A Abdulhaqq; David B Weiner
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 4.  DNA gene vaccination for HIV.

Authors:  J J Kim; D B Weiner
Journal:  Springer Semin Immunopathol       Date:  1997

5.  Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage.

Authors:  S André; B Seed; J Eberle; W Schraut; A Bültmann; J Haas
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

Review 6.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

7.  Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.

Authors:  M A Egan; W A Charini; M J Kuroda; J E Schmitz; P Racz; K Tenner-Racz; K Manson; M Wyand; M A Lifton; C E Nickerson; T Fu; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.

Authors:  J Richardson; A Moraillon; S Baud; A M Cuisinier; P Sonigo; G Pancino
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Bharti P Nehete; Stephanie J Buchl; Donna Palmer; David C Montefiori; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.